- Home
- EDIT vs LE Comparison
EDIT vs LE Comparison
Compare EDIT & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- LE
- Stock Information
- Founded
- EDIT 2013
- LE 1963
- Country
- EDIT United States
- LE United States
- Employees
- EDIT N/A
- LE N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- LE Clothing/Shoe/Accessory Stores
- Sector
- EDIT Health Care
- LE Consumer Discretionary
- Exchange
- EDIT Nasdaq
- LE Nasdaq
- Market Cap
- EDIT 263.7M
- LE 280.4M
- IPO Year
- EDIT 2016
- LE N/A
- Fundamental
- Price
- EDIT $2.57
- LE $14.36
- Analyst Decision
- EDIT Buy
- LE Strong Buy
- Analyst Count
- EDIT 12
- LE 1
- Target Price
- EDIT $5.40
- LE $20.00
- AVG Volume (30 Days)
- EDIT 1.7M
- LE 381.6K
- Earning Date
- EDIT 08-12-2025
- LE 09-09-2025
- Dividend Yield
- EDIT N/A
- LE N/A
- EPS Growth
- EDIT N/A
- LE N/A
- EPS
- EDIT N/A
- LE 0.14
- Revenue
- EDIT $38,901,000.00
- LE $1,338,672,000.00
- Revenue This Year
- EDIT N/A
- LE $3.31
- Revenue Next Year
- EDIT N/A
- LE $2.34
- P/E Ratio
- EDIT N/A
- LE $107.07
- Revenue Growth
- EDIT N/A
- LE N/A
- 52 Week Low
- EDIT $0.91
- LE $7.65
- 52 Week High
- EDIT $4.12
- LE $19.88
- Technical
- Relative Strength Index (RSI)
- EDIT 46.57
- LE 66.03
- Support Level
- EDIT $2.66
- LE $13.59
- Resistance Level
- EDIT $2.78
- LE $14.87
- Average True Range (ATR)
- EDIT 0.22
- LE 0.67
- MACD
- EDIT -0.02
- LE 0.10
- Stochastic Oscillator
- EDIT 39.39
- LE 78.93
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.